{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:01:41Z","timestamp":1784548901341,"version":"3.55.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Immune Thrombocytopenia Purpura (ITP) is a hematological disorder, where its primary cause is unknown. This can be triggered through any secondary underlying diseases or other environmental agents such as drugs, vaccination, natural viral infections etc. After the introduction of COVID-19 vaccines, a 4-fold increase in ITP cases was observed globally. Many of the COVID-19 vaccines such as m-RNA and viral-vector vaccines already demonstrated a cause-effect relationship between the event of ITP and immunization.\n                    <jats:bold>Case presentation:<\/jats:bold>\n                    A 54\u2009year old diabetic patient presented to the hospital with complaints of gum bleeding and fatigue. He was diagnosed with severe ITP following COVID-19 vaccination with a platelet count of 5000\u2009cumm. Initially his condition was considered as idiopathic and the COVID-19 vaccine exposure (13\u2009days prior to the clinical presentation) was not suspected. Later the immunization timeline and onset of the reaction was traced by his hematologist. The patient underwent multiple platelet transfusions and was given corticosteroid therapy. The patient was followed for a period of 1\u2009year and throughout the follow-up period the patient had fluctuating platelets count, especially after tapering steroids.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    ITP in this case is found to have a consistent causal association to COVID-19 vaccination as per the World Health Organization Causality assessment algorithm and is categorized under vaccine product related reactions. One\u2009year follow-up conducted showed that the thrombocytopenia following COVID-19 vaccine may be prolonged.\n                  <\/jats:p>","DOI":"10.1177\/00185787241245914","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T04:22:40Z","timestamp":1714191760000},"page":"552-556","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Chronic Immune Thrombocytopenia Purpura Following COVID-19 Vaccination (ChAdOx1 \u2013nCov-19): A Case Report With OneYear Follow-Up"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-2312","authenticated-orcid":false,"given":"Merrin","family":"Mathew","sequence":"first","affiliation":[{"name":"JSS Academy of Higher Education and Research, Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rovin M.","family":"Theempalangad","sequence":"additional","affiliation":[{"name":"JSS Academy of Higher Education and Research, Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juny","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Gulf Medical University, Ajman, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Ravi","sequence":"additional","affiliation":[{"name":"JSS Academy of Higher Education and Research, Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Uptodate. Immune thrombocytopenia (ITP) in adults: clinical manifestations and diagnosis. Uptodate; 2023. Updated 2023. Accessed March 2 2023. https:\/\/www.uptodate.com\/contents\/immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis#H3"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01790.x"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.84.3.227"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1726-4901(10)70138-6"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-1111"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.09.017"},{"key":"e_1_3_3_8_2","volume-title":"Vaccines and related biological products advisory committee meeting","author":"Moderna","year":"2020","unstructured":"Moderna. MRNA-1272 sponsor briefing document. Vaccines and related biological products advisory committee meeting. FDA; 2020."},{"key":"e_1_3_3_9_2","volume-title":"Vaccines and related biological products advisory committee meeting","author":"Pfizer-BioNTech","year":"2020","unstructured":"Pfizer-BioNTech. Pfizer-BioNTech COVID-19 vaccine briefing document. Vaccines and related biological products advisory committee meeting. FDA; 2020."},{"key":"e_1_3_3_10_2","first-page":"341","article-title":"Immune thrombocytopenia following the Pfizer-biontech BNT162b2 mRNA COVID-19 vaccine","volume":"23","author":"Ganzel C","year":"2021","unstructured":"Ganzel C, Ben-Chetrit E. Immune thrombocytopenia following the Pfizer-biontech BNT162b2 mRNA COVID-19 vaccine. Isr Med Assoc J. 2021;23:341.","journal-title":"Isr Med Assoc J"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26132"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.030"},{"issue":"17","key":"e_1_3_3_13_2","first-page":"1","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination","volume":"2","author":"Pai M","year":"2021","unstructured":"Pai M, Chan B, Stall N, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination. Science Briefs. 2021;2(17):1-7.","journal-title":"Science Briefs"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840"},{"issue":"5","key":"e_1_3_3_15_2","article-title":"Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias family","volume":"2","author":"Noy\u00e9 M","year":"2022","unstructured":"Noy\u00e9 M, Lecompte T. Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias family. Eur Heart J. 2022;2(5):oeac056.","journal-title":"Eur Heart J"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.051"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.054"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.4103\/JLP.JLP_117_16"},{"issue":"3","key":"e_1_3_3_19_2","article-title":"Anti-platelet factor 4 immunoglobulin G levels in vaccine-induced immune thrombocytopenia and thrombosis: persistent positivity through 7 months","volume":"6","author":"Montague SJ","year":"2022","unstructured":"Montague SJ, Smith CW, Lodwick CS, et al. Anti-platelet factor 4 immunoglobulin G levels in vaccine-induced immune thrombocytopenia and thrombosis: persistent positivity through 7 months. Res Pr Thromb Haemost. 2022;6(3):e12707.","journal-title":"Res Pr Thromb Haemost"},{"issue":"11","key":"e_1_3_3_20_2","first-page":"996","article-title":"Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19)","volume":"138","author":"Paulsen FO","year":"2021","unstructured":"Paulsen FO, Schaefers C, Langer F, et al. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19). Blood. 2021;138(11):996-999.","journal-title":"Blood"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e306"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2015.211"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02866-1"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.07.085"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02778-w"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26366"},{"key":"e_1_3_3_27_2","unstructured":"Serum Institute of India. COVISHIELD \u2013 Fact sheet Eng-Hindi insert Ver.1.cdr. Accessed March 7 2023. https:\/\/www.seruminstitute.com\/pdf\/covishield_fact_sheet.pdf"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787241245914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787241245914","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787241245914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:03:21Z","timestamp":1784545401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787241245914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/00185787241245914"],"URL":"https:\/\/doi.org\/10.1177\/00185787241245914","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]}}}